We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 667.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCSRT
RNS Number : 2127E
Consort Medical PLC
02 November 2015
Consort Medical plc
2 November 2015
Notification of Change of Auditor
Consort Medical plc ('the Company') announces its intention to appoint KPMG LLP as auditor of the Company. The Company first reported its intention to hold a competitive audit tender process in its annual report & financial statements 2014-15. This was initiated in light of emerging best practice and the fact that the existing auditor, PWC had been incumbent for some time. A rigorous tender process was conducted, which resulted in the Consort Medical plc Board recommending that KPMG LLP be appointed as auditor of the Company with effect from the 2015-16 financial year. The appointment will be put to shareholders for approval at the next general meeting.
Accordingly, the Company announces that a statement of reasons ('The Statement') from PWC, confirming its resignation as the Company's auditor as a result of tender process, was received by the Company on 28 October 2015 in accordance with Section 519 of The Companies Act 2006. Copies of The Statement received and the covering letter have been submitted to The National Storage Mechanism and will shortly be available for inspection at http://www.morningstar.co.uk/uk/NSM.
Enquiries:
Consort Medical Tel: +44 1442 867 Jonathan Glenn - Chief Executive Officer 920 Richard Cotton - Chief Financial Officer FTI Consulting Tel: +44 203 727 Ben Atwell/ Simon Conway 1000
Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.
Our businesses
Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectables products, and the manufacture of devices for the point of care diagnostics market.
Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners.
We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Nottingham, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). To learn more about our company visit our website at www.consortmedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPKBDNBBDDADK
(END) Dow Jones Newswires
November 02, 2015 07:41 ET (12:41 GMT)
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions